Technical Analysis for MNTA - Momenta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 30.8 -3.36% -1.07
MNTA closed down 3.36 percent on Tuesday, February 25, 2020, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical MNTA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Outside Day Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
20 DMA Support Bullish -3.36%
Slingshot Bullish Bullish Swing Setup -3.36%
Overbought Stochastic Strength -3.36%
Gapped Down Weakness -3.36%
Doji - Bearish? Reversal -8.88%
New 52 Week High Strength -8.88%
Upper Bollinger Band Walk Strength -8.88%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules. Its complex molecules include polysaccharides, polypeptides, and proteins and antibodies. The company's complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for autoimmune and inflammatory diseases; M834 for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company's novel products comprise M402, a novel heparan sulfate mimetic that binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis; and the sialylation technology, which is a discovery program that is intended to modify immunoglobulin G antibodies in intravenous immunoglobulin, a drug to treat autoimmune and inflammatory diseases. It has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Immunology Antibodies Immune System Tumor Antibody Autoimmunity Monoclonal Antibody Autoimmune And Inflammatory Diseases Glycoproteins Metastasis Biosimilar Deep Vein Thrombosis Relapsing Remitting Multiple Sclerosis Acute Coronary Syndromes Immunoglobulin Therapy

Is MNTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 34.83
52 Week Low 9.51
Average Volume 1,300,635
200-Day Moving Average 16.36
50-Day Moving Average 25.73
20-Day Moving Average 31.38
10-Day Moving Average 32.39
Average True Range 1.60
ADX 39.11
+DI 25.75
-DI 21.88
Chandelier Exit (Long, 3 ATRs ) 30.04
Chandelier Exit (Short, 3 ATRs ) 31.90
Upper Bollinger Band 34.22
Lower Bollinger Band 28.53
Percent B (%b) 0.4
BandWidth 18.13
MACD Line 1.86
MACD Signal Line 2.25
MACD Histogram -0.3844
Fundamentals Value
Market Cap 2.27 Billion
Num Shares 73.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -48.13
Price-to-Sales 9.20
Price-to-Book 2.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.26
Resistance 3 (R3) 35.57 34.41 34.51
Resistance 2 (R2) 34.41 33.27 34.25 34.26
Resistance 1 (R1) 32.60 32.57 32.02 32.29 34.02
Pivot Point 31.44 31.44 31.15 31.28 31.44
Support 1 (S1) 29.63 30.30 29.05 29.32 27.58
Support 2 (S2) 28.47 29.60 28.31 27.34
Support 3 (S3) 26.66 28.47 27.09
Support 4 (S4) 26.35